Published in Am J Respir Crit Care Med on April 07, 2011
BUILD 3: Bosentan Use in Interstitial Lung Disease (BUILD 3) | NCT00391443
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51
Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med (2013) 1.89
Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol (2011) 1.82
Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2014) 1.73
Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. Chest (2014) 1.51
Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest (2014) 1.25
A review of current and novel therapies for idiopathic pulmonary fibrosis. J Thorac Dis (2013) 1.18
Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res (2013) 1.10
Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest (2013) 1.05
The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med (2012) 1.04
New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. Am J Respir Crit Care Med (2014) 1.02
Echocardiographic and hemodynamic predictors of mortality in idiopathic pulmonary fibrosis. Chest (2013) 1.02
Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project. Lung (2012) 0.98
The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance. Eur Respir J (2013) 0.95
Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis. Curr Opin Pharmacol (2013) 0.94
Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol (2014) 0.94
Severe pulmonary hypertension in idiopathic nonspecific interstitial pneumonia. Pulm Circ (2012) 0.94
Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Des Devel Ther (2012) 0.93
Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nat Rev Drug Discov (2015) 0.93
Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription. Am J Physiol Cell Physiol (2014) 0.92
Update on diagnosis and treatment of idiopathic pulmonary fibrosis. J Bras Pneumol (2015) 0.92
Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag (2015) 0.91
Medical therapy of stricturing Crohn's disease: what the gut can learn from other organs - a systematic review. Fibrogenesis Tissue Repair (2014) 0.89
Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials. PLoS One (2012) 0.89
Interstitial lung disease in scleroderma. Rheum Dis Clin North Am (2015) 0.88
Patient-reported outcomes in idiopathic pulmonary fibrosis research. Chest (2012) 0.88
Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. Multidiscip Respir Med (2012) 0.87
The treatment of idiopathic pulmonary fibrosis. F1000Prime Rep (2014) 0.86
Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now? Drugs (2016) 0.85
Protein tyrosine phosphatase α mediates profibrotic signaling in lung fibroblasts through TGF-β responsiveness. Am J Pathol (2014) 0.85
Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Proposal. Curr Respir Care Rep (2013) 0.84
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. Biomed Res Int (2015) 0.83
Mechanisms, Management, and Treatment of Fibrosis in Patients with Inflammatory Bowel Diseases. Gastroenterology (2016) 0.83
Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts. Respir Res (2012) 0.83
Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. PLoS One (2015) 0.83
Plasma endothelin-1 and vascular endothelial growth factor levels and their relationship to hemodynamics in idiopathic pulmonary fibrosis. Respiration (2012) 0.83
Acute exacerbations in patients with idiopathic pulmonary fibrosis. Respir Res (2013) 0.83
Pulmonary hypertension and right heart dysfunction in chronic lung disease. Biomed Res Int (2014) 0.82
Idiopathic pulmonary fibrosis: early detection and referral. Respir Med (2014) 0.82
Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future. Ann Med (2015) 0.81
End of an ERA: lessons from negative clinical trials in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 0.81
Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design? Drug Des Devel Ther (2014) 0.81
Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Ther Adv Musculoskelet Dis (2015) 0.80
Diagnostic workup for diffuse parenchymal lung disease: schematic flowchart, literature review, and pitfalls. Lung (2012) 0.80
Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Med (2016) 0.79
Managing comorbidities in idiopathic pulmonary fibrosis. Int J Gen Med (2015) 0.79
Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts. Arthritis Res Ther (2015) 0.79
The diagnosis and treatment of idiopathic pulmonary fibrosis. Dtsch Arztebl Int (2013) 0.78
Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases. Biomed Res Int (2015) 0.78
Clinical trials and tribulations--lessons from pulmonary fibrosis. QJM (2012) 0.78
Pulmonary hypertension in parenchymal lung disease. Pulm Med (2012) 0.77
Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ETA Versus ETB Receptors and on the Functionality of Endothelial ETB Receptors. J Cardiovasc Pharmacol (2015) 0.77
Regulation and Relevance of Myofibroblast Responses in Idiopathic Pulmonary Fibrosis. Curr Pathobiol Rep (2013) 0.77
Reversibility of Stricturing Crohn's Disease-Fact or Fiction? Inflamm Bowel Dis (2016) 0.77
Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis. Ther Clin Risk Manag (2016) 0.77
Taking the "I" out of IPF. Eur Respir J (2015) 0.77
Macitentan for the treatment of pulmonary arterial hypertension. Vasc Health Risk Manag (2014) 0.77
miR-18a-5p Inhibits Sub-pleural Pulmonary Fibrosis by Targeting TGF-β Receptor II. Mol Ther (2017) 0.77
Scleroderma therapy: clinical overview of current trends and future perspective. Rheumatol Int (2012) 0.76
Recent advances in idiopathic pulmonary fibrosis. Tuberc Respir Dis (Seoul) (2013) 0.76
Pulmonary arterial hypertension treatment guidelines: new answers and even more questions. Chest (2014) 0.76
Ambroxol hydrochloride in the management of idiopathic pulmonary fibrosis: Clinical trials are the need of the hour. Lung India (2014) 0.75
Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials. J Am Heart Assoc (2016) 0.75
Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension due to lung diseases and/or hypoxia. Ann Thorac Med (2014) 0.75
A case of anti-aminoacyl tRNA synthetase (ARS) antibody-positive polymyositis (PM)/dermatomyositis (DM)-associated interstitial pneumonia (IP) successfully controlled with bosentan therapy. Respir Med Case Rep (2017) 0.75
Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy. Core Evid (2016) 0.75
Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations. Clin Med Insights Circ Respir Pulm Med (2016) 0.75
Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) registry. BMJ Open Respir Res (2016) 0.75
Nrf2 inhibits epithelial-mesenchymal transition by suppressing snail expression during pulmonary fibrosis. Sci Rep (2016) 0.75
Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis. Respir Med Case Rep (2014) 0.75
The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. Respir Med (2015) 0.75
MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis. ERJ Open Res (2017) 0.75
Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials. Eur J Clin Pharmacol (2016) 0.75
Pulmonary hypertension associated with lung diseases and hypoxemia. Heart Fail Rev (2016) 0.75
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Bosentan therapy for pulmonary arterial hypertension. N Engl J Med (2002) 11.18
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 10.62
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med (2003) 10.40
Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity (2009) 9.01
Genetic epidemiology of COPD (COPDGene) study design. COPD (2010) 7.67
High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2005) 7.20
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med (2011) 6.74
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51
A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med (2011) 6.40
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med (2015) 6.03
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med (2004) 6.02
Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A (2007) 5.95
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (2011) 5.94
Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol (2005) 5.88
Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med (2008) 5.82
Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med (2001) 5.76
Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med (2012) 5.54
An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med (2012) 5.37
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33
Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med (2011) 4.75
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol (2004) 4.37
Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med (2005) 4.25
The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med (2005) 4.25
The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med (2005) 4.15
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97
Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation (2013) 3.90
Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2003) 3.89
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med (2011) 3.85
Sarcoidosis. Lancet (2003) 3.60
Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest (2006) 3.59
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 3.49
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum (2006) 3.45
Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med (2006) 3.32
Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology (2011) 3.30
Dasty2, an Ajax protein DAS client. Bioinformatics (2008) 3.26
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet (2009) 3.21
Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med (2008) 3.19
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet (2013) 3.17
Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol (2011) 3.08
Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med (2003) 3.07
Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med (2002) 3.06
Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med (2010) 3.05
Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med (2003) 3.00
Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med (2004) 2.97
A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med (2007) 2.95
6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J (2013) 2.92
Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol (2005) 2.91
Pulmonary fibrosis associated with aluminum trihydrate (Corian) dust. N Engl J Med (2014) 2.88
FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J (2013) 2.87
Acute respiratory failure after interferon-gamma therapy of end-stage pulmonary fibrosis. Am J Respir Crit Care Med (2003) 2.84
Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med (2003) 2.78
Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum (2011) 2.74
Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol (2013) 2.74
Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med (2007) 2.66
Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med (2008) 2.65
Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med (2011) 2.62
Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med (2011) 2.62
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 2.54
Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest (2010) 2.51
Baseline characteristics of participants in the randomized national lung screening trial. J Natl Cancer Inst (2010) 2.50
Human pulmonary chimerism after hematopoietic stem cell transplantation. Am J Respir Crit Care Med (2003) 2.50
Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol (2002) 2.43
Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med (2004) 2.42
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med (2010) 2.40
Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology (2002) 2.37